In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions.


Journal

Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 07 01 2020
revised: 04 02 2020
accepted: 12 02 2020
pubmed: 18 2 2020
medline: 3 11 2020
entrez: 18 2 2020
Statut: ppublish

Résumé

Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative complications. The present retrospective analysis of a preliminary case series of 25 women diagnosed with Hodgkin or non-Hodgkin lymphoma aims to evaluate the feasibility of IVM for urgent fertility preservation purposes in hematological context. A median of five mature oocytes was cryopreserved after one cycle of IVM, performed without delaying the start of the chemotherapy (median delay from histological diagnosis to start of the chemotherapy 17.5 days). No association was found between lymphomas' characteristics and the number of recovered or frozen oocytes. Although experimental, this technique could be relevant when fertility preservation has to be performed within a short time frame and without additional surgery nor any risk of malignant cells reintroduction.

Identifiants

pubmed: 32065670
doi: 10.1002/hon.2724
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

560-564

Informations de copyright

© 2020 John Wiley & Sons Ltd.

Références

Practice Committee of American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013;100(5):1214-1223. https://doi.org/10.1016/j.fertnstert.2013.08.012.
Practice Committee ISFP, Kim SS, Donnez J, et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet. 2012;29(6):465-468. https://doi.org/10.1007/s10815-012-9786-y.
Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice guideline update. J Clin Oncol. 2013;31(19):2500-2510. https://doi.org/10.1200/JCO.2013.49.2678.
Jadoul P, Kim SS. ISFP Practice Committee. Fertility considerations in young women with hematological malignancies. J Assist Reprod Genet. 2012;29(6):479-487. https://doi.org/10.1007/s10815-012-9792-0.
Rao GD, Tan SL. In vitro maturation of oocytes. Semin Reprod Med. 2005;23(3):242-247. https://doi.org/10.1055/s-2005-872452.
Huang JYJ, Tulandi T, Holzer H, Tan SL, Chian R-C. Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation. Fertil Steril. 2008;89(3):567-572. https://doi.org/10.1016/j.fertnstert.2007.03.090.
Berwanger AL, Finet A, El Hachem H, le Parco S, Hesters L, Grynberg M. New trends in female fertility preservation: in vitro maturation of oocytes. Future Oncol. 2012;8(12):1567-1573. https://doi.org/10.2217/fon.12.144.
Grynberg M, El Hachem H, de Bantel A, Benard J, le Parco S, Fanchin R. In vitro maturation of oocytes: uncommon indications. Fertil Steril. 2013;99(5):1182-1188. https://doi.org/10.1016/j.fertnstert.2013.01.090.
Grynberg M, Dagher Hayeck B, Papanikolaou EG, Sifer C, Sermondade N, Sonigo C. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro. Hum Reprod. 2019;34(2):374-379. https://doi.org/10.1093/humrep/dey358.
Sermondade N, Sonigo C, Sifer C, et al. Serum antimüllerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation. Fertil Steril. 2019;111(2):357-362. https://doi.org/10.1016/j.fertnstert.2018.10.018.
Sonigo C, Simon C, Boubaya M, et al. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation? Hum Reprod. 2016;31(7):1493-1500. https://doi.org/10.1093/humrep/dew102.
Quinn GP, Vadaparampil ST, Lee J-H, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952-5957. https://doi.org/10.1200/JCO.2009.23.0250.
Quinn GP, Block RG, Clayman ML, et al. If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients' medical records. J Oncol Pract. 2015;11(2):137-144. https://doi.org/10.1200/JOP.2014.000786.
Allen PB, Pavone ME, Smith KN, et al. The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-Centre experience. Br J Haematol. 2018;180(6):901-904. https://doi.org/10.1111/bjh.14466.
Grynberg M, Poulain M, le Parco S, Sifer C, Fanchin R, Frydman N. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients. Hum Reprod. 2016;31(3):623-629. https://doi.org/10.1093/humrep/dev325.
Seyhan A, Ata B, Son W-Y, Dahan MH, Tan SL. Comparison of complication rates and pain scores after transvaginal ultrasound-guided oocyte pickup procedures for in vitro maturation and in vitro fertilization cycles. Fertil Steril. 2014;101(3):705-709. https://doi.org/10.1016/j.fertnstert.2013.12.011.
Tulandi T, Holzer H. Effects of malignancies on the gonadal function. Fertil Steril. 2012;98(4):813-815. https://doi.org/10.1016/j.fertnstert.2012.05.010.
Lawrenz B, Fehm T, von Wolff M, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma-evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril. 2012;98(1):141-144. https://doi.org/10.1016/j.fertnstert.2012.04.021.
Sonigo C, Comtet M, Duros S, Sifer C, Sermondade N, Grynberg M. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation. J Assist Reprod Genet. 2018;35(1):91-97. https://doi.org/10.1007/s10815-017-1059-3.
Segers I, Mateizel I, Van Moer E, et al. In vitro maturation (IVM) of oocytes recovered from ovariectomy specimens in the laboratory: a promising “ex vivo” method of oocyte cryopreservation resulting in the first report of an ongoing pregnancy in Europe. J Assist Reprod Genet. 2015;32(8):1221-1231. https://doi.org/10.1007/s10815-015-0528-9.
Creux H, Monnier P, Son W-Y, Buckett W. Thirteen years' experience in fertility preservation for cancer patients after in vitro fertilization and in vitro maturation treatments. J Assist Reprod Genet. 2018;35(4):583-592. https://doi.org/10.1007/s10815-018-1138-0.
Prasath EB, Chan MLH, Wong WHW, et al. First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient. Hum Reprod. 2014;29(2):276-278. https://doi.org/10.1093/humrep/det420.
Uzelac PS, Delaney AA, Christensen GL, Bohler HCL, Nakajima ST. Live birth following in vitro maturation of oocytes retrieved from extracorporeal ovarian tissue aspiration and embryo cryopreservation for 5 years. Fertil Steril. 2015;104(5):1258-1260. https://doi.org/10.1016/j.fertnstert.2015.07.1148.
Zhang XY, Ata B, Son W-Y, Buckett WM, Tan S-L, Ao A. Chromosome abnormality rates in human embryos obtained from in-vitro maturation and IVF treatment cycles. Reprod Biomed Online. 2010;21(4):552-559. https://doi.org/10.1016/j.rbmo.2010.05.002.
Yakut T, Karkucak M, Sher G, Keskintepe L. Comparison of aneuploidy frequencies between in vitro matured and unstimulated cycles oocytes by metaphase comparative genomic hybridization (mCGH). Mol Biol Rep. 2012;39(5):6187-6191. https://doi.org/10.1007/s11033-011-1436-4.

Auteurs

Charlotte Sonigo (C)

Department of Reproductive Medicine and Fertility Preservation, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique - Hôpitaux de Paris, Bondy, France.
Inserm U1185 Université Paris-Sud, Université Paris Saclay, Le Kremlin Bicêtre, France.

Jeanne Bajeux (J)

Department of Reproductive Medicine and Fertility Preservation, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique - Hôpitaux de Paris, Bondy, France.

Marouane Boubaya (M)

Département de recherche clinique, Groupe Hospitalier Paris Seine Saint Denis, Assistance Publique -Hôpitaux de Paris, Université Paris 13, Bobigny et INSERM U1153, Paris, France.

Florence Eustache (F)

Department of Cytogenetic and Reproductive Biology, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique - Hôpitaux de Paris, Bondy, France.

Christophe Sifer (C)

Department of Cytogenetic and Reproductive Biology, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique - Hôpitaux de Paris, Bondy, France.

Vincent Lévy (V)

Département de recherche clinique, Groupe Hospitalier Paris Seine Saint Denis, Assistance Publique -Hôpitaux de Paris, Université Paris 13, Bobigny et INSERM U1153, Paris, France.

Michaël Grynberg (M)

Department of Reproductive Medicine and Fertility Preservation, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique - Hôpitaux de Paris, Bondy, France.
Inserm U1185 Université Paris-Sud, Université Paris Saclay, Le Kremlin Bicêtre, France.
Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris 13, Communauté d'Universités et Etablissements Sorbonne Paris Cité, Paris, France Inserm U1133 Université Paris Diderot, Paris, France.

Nathalie Sermondade (N)

Department of Cytogenetic and Reproductive Biology, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance Publique - Hôpitaux de Paris, Bondy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH